Claims
- 1. A peptide fragment of plasminogen which has been modified to ensure a linear conformation of the peptide fragment.
- 2. The modified peptide fragment of claim 1 comprising SEQ ID NO: 1, 2,4,5,6,7,9, 10, 11, 12 or 13.
- 3. A composition for inhibition of angiogenesis comprising a modified peptide fragment of claim 1 which exhibits anti-angiogenic activity and a pharmaceutically acceptable vehicle.
- 4. The composition of claim 3 wherein the modified peptide fragment comprises SEQ ID NO: 2, 4, 5, 6, 12 or 13.
- 5. A method for inhibiting angiogenesis which comprises contacting cells with a modified peptide fragment of claim 1.
- 6. A method for treating an angiogenic dependent and associated disorder in a subject comprising administering to the subject an effective amount of a composition of claim 3.
- 7. The method of claim 6 wherein the angiogenic dependent and associated disorder comprises a solid tumor, a blood borne tumor, tumor metastasis, a benign tumor, rheumatoid arthritis, psoriasis, an ocular angiogenic disease, Osler-Webber Syndrome, myocardial angiogenesis, plaque neovascularization, telangiectasia, hemophiliac joints, angiofibroma, or wound granulations.
- 8. A method for treating a disease or condition of excessive or abnormal stimulation of endothelial cells in a subject comprising administering to the subject an effective amount of a composition of claim 3.
- 9. The method of claim 8 wherein the disease or conditions comprises intestinal adhesions, atherosclerosis, scleroderma or hypertrophic scars.
- 10. A method for identifying potential inhibitors of angiogenesis comprising identifying peptide fragments of plasminogen with a linear conformation and assessing anti-angiogenic activity of the linear fragment.
RELATED APPLICATIONS
[0001] This application claims priority benefit under Title 35 § 119(e) of U.S. provisional Application No. 60/245,384, filed Nov. 2, 2000.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60245384 |
Nov 2000 |
US |